Covalon Technologies Ltd V.COV

Alternate Symbol(s): CVALF

Healthcare Biotechnology

Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon’s name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.

TSXV:COV - Post by User

Covalon Technologies Ltd

Bullboard Posts

Comment by zenvestingon Jan 03, 2017 11:24pm

156 Views

Post# 25664553

RE:Minimum $20 million in F2017 Sales

TheRock07 deserves a pat on the back for his foresight in making this post in August.

TheRock07 wrote: Fiscal 2017 begins in october 2016.

By my estimation, Covalon will have at least $20 million in sales in F2017.

1....$11.1 million for delivery in F2017 to SA ministry of health

2.....Covalon Technologies Ltd., through its exclusive distribution partner, was awarded a tender for both IV Clear and SurgiClear products at the prestigious King Abdullah Medical City in Mecca, Saudi Arabia.

With over 1,500 beds, King Abdullah Medical City is one of the most influential hospitals in the Middle East given its location in Mecca where over 14 million people will visit over the next 15 weeks.

We have a very strong team in Saudi Arabia that visits hospitals like King Abdullah Medical City everyday to introduce and support the sale of our products. My estimate is $ 2+ million

COV have a very strong team in Saudi Arabia that visits hospitals like King Abdullah Medical City everyday to introduce and support the sale of their products.

3.....COV have a private contract with the Healkth Oasis hospital in Riyadh

My estimate is $0.8 + million

4...COV have another contract with the International Medical Center in Jeddah

My estimate is $0.8+ million

5....COV have signed contracts with Iran, UAE and Qatar which, combined, have an health care sector that is twice that of SA.

My estimate is $2.5 + million

Total for Middle East for F2017 = $17.2 million.

This is from contracts already in place, and COV will be awarded other contracts in the ME within the coming fiscal year.

In other words, covalon needs only about $3 million from Latin America and the US to hit the $20 million mark for F2017.

That will be a piece of cake.

And more will be coming from China and the other 8 latin America countries for which a distributor is now being identified.

COV is a steal at these prices, with its peers trading well over 8 times annual sales.

And why Abe is reluctant to sell those 350,000 shares